Stock ENBI ENTHEON BIOMEDICAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Entheon Biomedical Corp. Stock

Equities

ENBI

CA29383X2023

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 02:03:53 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.155 CAD 0.00% Intraday chart for Entheon Biomedical Corp. 0.00% +55.00%
Apr. 18 Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding CI
Apr. 11 Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding CI

Financials

Sales 2022 0.19 0.26 Sales 2023 0.25 0.34 Capitalization 591K 806K
Net income 2022 -8M -10.92M Net income 2023 - 0 EV / Sales 2022 5,759,850 x
Net cash position 2022 680K 928K Net cash position 2023 345K 470K EV / Sales 2023 983,765 x
P/E ratio 2022
-0.21 x
P/E ratio 2023
-1.97 x
Employees 2
Yield 2022 *
-
Yield 2023
-
Free-Float 97.86%
More Fundamentals * Assessed data

Chart Entheon Biomedical Corp.

Dynamic Chart

Latest news about Entheon Biomedical Corp.

Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding CI
Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding CI
Entheon Biomedical Corp. Reports Earnings Results for the Full Year Ended November 30, 2023 CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023 CI
Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023 CI
Heading Health Inc. announced that it has received $4.5 million in funding from a group of investors CI
Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 28, 2023 CI
Entheon Biomedical Corp. Announces Termination of Consulting Agreement with Cybin CI
Entheon Biomedical Corp. Auditor Raises 'Going Concern' Doubt CI
Entheon Biomedical Corp. Announces Resignation of Ruth Chun as Director CI
Entheon Biomedical Corp. Announces CFO Changes CI
Entheon Biomedical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022 CI
Entheon Biomedical Corp. Closes Patient Enrolment in its Clinical Research Study EBIQ-101 CI
Entheon Biomedical Corp. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022 CI
More news

Press releases Entheon Biomedical Corp.

Entheon Biomedical : CFO Certification PU
Entheon Biomedical : CEO Certification PU
Entheon Biomedical : Quarterly Report PU
Entheon Biomedical : CFO Certification PU
Entheon Biomedical : CEO Certification PU
More press releases

News in other languages on Entheon Biomedical Corp.

IRW-News: Entheon Biomedical Corp.: HaluGen Life Sciences, eine hundertprozentige Tochtergesellschaft von Entheon Biomedical, und die Firma Silo Wellness gründen eine Partnerschaft für Psychedelika-Gentest-Kits
IRW-News: Entheon Biomedical Corp.: Entheon Biomedical Corp. meldet Vereinbarung zur Übernahme von Lobo Genetics Inc.
IRW-News: Entheon Biomedical Corp.: Der genetische Psychedelika-Test von HaluGen Life Sciences, einem hundertprozentigen Tochterunternehmen von Entheon Biomedical, ist jetzt in den USA zum Verkauf verfügbar
IRW-News: Entheon Biomedical Corp.: Entheon Biomedical unterzeichnet Liefervereinbarung für DMT-Arzneimittelsubstanzen mit F&E-Spezialisten Ofichem
IRW-News: Entheon Biomedical Corp.: Entheon Biomedical Corp. informiert über Neuigkeiten aus dem Unternehmen
More news

Quotes and Performance

Current month-22.50%
1 month+40.91%
3 months+55.00%
6 months+55.00%
Current year+55.00%
More quotes

Highs and lows

1 week
0.16
Extreme 0.155
0.23
1 month
0.10
Extreme 0.095
0.25
Current year
0.05
Extreme 0.05
0.40
1 year
0.05
Extreme 0.05
0.40
3 years
0.05
Extreme 0.05
7.10
5 years
0.05
Extreme 0.05
13.50
10 years
0.05
Extreme 0.05
13.50
More quotes

Managers and Directors - Entheon Biomedical Corp.

Managers TitleAgeSince
Timothy Ko CEO
 Chief Executive Officer 39 19-06-30
Soo-Whan Kim DFI
 Director of Finance/CFO - 23-01-06
Andrew Hegle BRD
 Director/Board Member 46 19-12-31
Members of the board TitleAgeSince
Timothy Ko CEO
 Chief Executive Officer 39 19-06-30
Andrew Hegle BRD
 Director/Board Member 46 19-12-31
Christopher Gondi BRD
 Director/Board Member 53 20-11-04
More insiders

Quotes

Date Price Change Volume
24-04-25 0.155 -22.50% 500
24-04-24 0.2 -13.04% 53,817
24-04-22 0.23 +43.75% 1,600
24-04-19 0.16 +3.23% 29,200
24-04-18 0.155 +3.33% 105,000

Delayed Quote Canadian Securities Exchange, April 25, 2024 at 02:03 pm EDT

More quotes

Company Profile

Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is focused on treating addiction and substance-use disorders.
Sector
Biotechnology & Medical Research
Calendar
2024-04-25 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENTHEON BIOMEDICAL CORP. Stock Entheon Biomedical Corp.
+55.00% 1M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+46.73% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 11.7B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.05B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ENBI Stock